Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to



Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate
Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in
Humans

Scientific Poster Presentation This Week at ACG 2012

NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.
(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders
and diseases, today announced a presentation on SP-333, the company's second
investigational drug from the guanylate cyclase-C agonist class, at the
American College of Gastroenterology 77^th annual meeting, which is being held
in Las Vegas, NV from October 19-24, 2012. The presentation highlights
pioneering research demonstrating that SP-333 ameliorates colitis in mice
through inhibition of NF-kappa B activation. SP-333 recently entered clinical
trials as an experimental drug for the treatment of ulcerative colitis, and is
presently in a Phase I trial in healthy volunteers.

The poster presentation is on Sunday October 21, 2012 from 3:30-7:00PM in
Exhibit Hall B at The Venetian.

Poster Title:SP-333, a Proteolysis-resistant Agonist of Guanylate Cyclase-C,
Inhibits Activation of NF-ĸB and Suppresses Production of Inflammatory
Cytokines to Ameliorate DSS-induced Colitis in Mice (P414), authored by Graham
Zhang, Krishna P. Arjunan, John A. Foss, Stephen J. Comiskey and Kunwar
Shailubhai.

"SP-333 is a highly potent oral drug candidate for treatment of GI
inflammatory diseases," stated Dr. Gary S. Jacob, President and CEO of Synergy
Pharmaceuticals. "SP-333 broadens our clinical portfolio of novel GC-C
agonists for treatment of GI disorders and diseases."

"The transcription factor NF-ĸappa B is known to be abnormally active in many
inflammatory diseases and cancers," said Dr. Kunwar Shailubhai, Chief
Scientific Officer of Synergy Pharmaceuticals. "The study we report here,
demonstrating that treatment with SP-333 inhibits activation of NF-kappa B, is
an exciting scientific finding that opens a new avenue for treatment of
ulcerative colitis. Oral treatment with SP-333, a first-in-class guanylate
cyclase-C (GC-C) agonist to treat ulcerative colitis, showed impressive
anti-inflammatory activity in experimental models of colitis in mice."

About SP-333

SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone which is
normally produced in the body's intestinal tract. Deficiency of uroguanylin is
likely to be one of the primary reasons associated with formation of polyps as
well as debilitating and difficult-to-treat GI inflammatory disorders such as
ulcerative colitis and Crohn's disease. Orally-administered SP-333 binds to
and activates guanylate cyclase C (GC-C) expressed on epithelial cells lining
the GI mucosa, resulting in stimulation of cyclic GMP in target tissues.
SP-333 has been found to be highly stable against proteolysis in simulated
intestinal fluid for up to 24 hours. Its enhanced stability makes this peptide
an extremely potent GC-C agonist in animal studies in mice and monkeys,
promoting bowel movement in monkeys, and ameliorating GI inflammation in mice,
respectively.

About Plecanatide

Plecanatide is a member of a new class of essentially non-systemic drugs,
referred to as guanylate cyclase C (GC-C) agonists, which are currently in
development to treat CIC and IBS-C. Plecanatide is a synthetic analog of
uroguanylin, a natriuretic hormone that regulates ion and fluid transport in
the GI tract. Orally-administered plecanatide binds to and activates GC-C
receptors expressed on epithelial cells lining the GI mucosa, resulting in
activation of the cystic fibrosis transmembrane conductance regulator (CFTR),
and leading to augmented flow of chloride and water into the lumen of the gut.
Activation of the GC-C receptor pathway is believed to facilitate bowel
movement as well as producing other beneficial physiological responses
including improvement in abdominal pain and inflammation. In animal models,
oral administration of plecanatide promotes intestinal secretion and also
ameliorates GI inflammation.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate plecanatide is a synthetic analog of the human gastrointestinal
(GI) hormone uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a Phase I
study of plecanatide in healthy volunteers and a Phase IIa clinical trial in
chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy
initiated dosing of patients in a major Phase II/III clinical trial of
plecanatide to treat CIC. Plecanatide is also being developed to treat
constipation-predominant irritable bowel syndrome (IBS-C), with the first
trial in IBS-C patients planned for the second half of 2012. Synergy's second
GC-C agonist SP-333 is in clinical development to treat inflammatory bowel
diseases, and is presently in a Phase I trial in healthy volunteers. More
information is available at http://www.synergypharma.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "planned," "believe," "forecast," "estimated," "expected," and
"intend," among others. These forward-looking statements are based on
Synergy's current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, substantial competition; our ability
to continue as a going concern; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of government
or third party payer reimbursement; limited sales and marketing efforts and
dependence upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As with any
pharmaceutical under development, there are significant risks in the
development, regulatory approval and commercialization of new products. There
are no guarantees that future clinical trials discussed in this press release
will be completed or successful or that any product will receive regulatory
approval for any indication or prove to be commercially successful. Investors
should read the risk factors set forth in Synergy's Form 10-K for the year
ended December 31, 2011 and other periodic reports filed with the Securities
and Exchange Commission. While the list of factors presented here is
considered representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted factors may
present significant additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as of the date
hereof, and Synergy does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.

CONTACT: Media Contact:
         Janet Skidmore
         Office:  215-658-4915
         Mobile:  215-429-2917
         skidmorecomm@earthlink.net
        
         Investor Contact:
         Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement